I

Immunovant

D
IMVT
USD
-1.47
(-4.6785%)
Market Closed
27,736.00
Volume
-1.402
EPS
-
Div Yield
-15.900524
P/E
4,383,702,851.30
Market Cap
Today
-4.6785%
1 Week
2.393%
1 Month
1.784%
6 Months
1.285%
12 Months
-13.339%
Year To Date
-28.911%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
AFRM
-0.01
(-0.0205%)
USD
S
SQ
-2.38
(-3.065%)
USD
PYPL
PYPL
-0.03
(-0.0369%)
USD
V
V
-1.66
(-0.54%)
USD
AXP
AXP
10.79
(3.9087%)
USD
MA
MA
-3.15
(-0.6045%)
USD
AAPL
AAPL
5
(2.2453%)
USD
AMZN
AMZN
3.02
(1.4575%)
USD

Title:
Immunovant

Sector:
Healthcare
Industry:
Biotechnology
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Do you need help or have a question?
Contact Us